Phase Ib Trial of HER2/Neu Peptide (E75) Vaccine in Breast Cancer Patients at Risk for Recurrence After Surgical and Medical Therapies.

Trial Profile

Phase Ib Trial of HER2/Neu Peptide (E75) Vaccine in Breast Cancer Patients at Risk for Recurrence After Surgical and Medical Therapies.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Jul 2014

At a glance

  • Drugs Nelipepimut-S (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Oct 2013 Results have been presented at the American College of Surgeons Clinical Congress 2013 according to a Galena Biopharma media release. Results were also summarised in the media release.
    • 05 Jun 2013 Results of this trial and SN 34 [Profile 700020466] presented at American Society of Clinical Oncologists (ASCO) 2013 Annual Meeting, according to a Galena Biopharma media release.
    • 12 Mar 2013 Data has been presented at the 27th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), according to a Galena Biopharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top